Found 117 clinical trials
The study will examine the effects that Metformin Hydrochloride has on Prostate Specific Antigen levels in men with Prostate Cancer.
The study will examine the effects that Metformin Hydrochloride has on Prostate Specific Antigen levels in men with Prostate Cancer.
- 70 views
- 23 Nov, 2020
- 1 location
A multicenter clinical study of the Sonablate® 500 (Sonablate) for the TreAtment of locally Recurrent prostate cancer with HIFU(STAR Trial)
A multicenter clinical study of the Sonablate® 500 (Sonablate) for the TreAtment of locally Recurrent prostate cancer with HIFU(STAR Trial)
- 229 views
- 25 Mar, 2021
- 1 location
PSMA-PET Registry for Recurrent Prostate Cancer (PREP)
This study aims to institute a province-wide registry leveraging the availability of a new Positron Emission Tomography tracer, [18F]-DCFPyL and PET expertise across Ontario centers to improve our ability to characterize patterns of recurrence and personalize therapies in men with recurrent prostate cancer after primary treatment.
- 108 views
- 04 Apr, 2023
- 6 locations
Randomized Controlled Trial of Anti-inflammatory Medications in Patients With Elevated Serum Prostate-specific Antigen
The purpose of this study is to assess the impact of ibuprofen in men with elevated serum PSA.
- 0 views
- 22 Oct, 2022
- 1 location
The Correlation Between the Detection Rate of 18F-FACBC PET/CT and the PSA Kinetics for Prostate Cancer Patients With Biochemical Recurrence.
. The treatment decision planning is made up by clinical charts like Gleason score (GS), TNM stage and serum prostate-specific antigen (PSA) level. However, after definitive therapy for PCa with either
- 0 views
- 13 Oct, 2022
- 1 location
A Trial to Find Out if REGN4336 is Safe and How Well it Works Alone and in Combination With Cemiplimab for Adut Participants With Advanced Prostate Cancer
> To assess preliminary anti-tumor activity of REGN4336 as monotherapy or in combination with cemiplimab as measured by prostate specific antigen (PSA) decline To evaluate
- 6 views
- 06 Apr, 2023
- 8 locations
Radium-223 in Biochemically Recurrent Prostate Cancer
prostate cancer and induced immune changes earlier in the disease when the cancer is only detectable by prostate specific antigen (PSA) in the blood. Objective To
- 0 views
- 03 Apr, 2023
- 1 location
Partial Prostate Salvage High Dose Rate Brachytherapy (SalvageHDR)
A dose-response relationship for radiation in the management of prostate cancer is well established. Local recurrence of prostate cancer after external beam radiotherapy occurs in at least 40% of patients treated because of inability to deliver sufficient dose through external beam techniques. These patients respond well to re-irradiation using brachytherapy …
- 4 views
- 25 Feb, 2022
- 1 location
18F-fluciclovine PET in Metastatic Castration Resistant Prostate Cancer Treated With Life Prolonging Therapies
This is a pilot phase 2 single-arm study, of men with metastatic castration-resistant prostate cancer (mCRPC). Patients will be treated with any of the approved life-prolonging therapies: abiraterone 1000 mg daily plus prednisone 5 mg (or dexamethasone 0.5 mg) daily, enzalutamide 160 mg daily, or docetaxel 50 mg/m2 every two …
- 0 views
- 21 Oct, 2021
- 1 location
Phase II Trial of 18F-DCFPyL Imaging as a Method to Assess Treatment Response to Stereotactic Body Radiation Therapy
Background Identifying medium- and high-risk prostate cancer early may allow for treatments to work. But identification can be hard. Researchers want to see if a radiotracer used during PET scans can help. Objective To test how an imaging agent called 18F-DCFPyL detects response to standard prostate cancer treatment. Eligibility People …
- 0 views
- 27 Oct, 2022
- 1 location